ABVC BIOPHARMA, INC. Quarterly Debt-to-equity in % from Q4 2016 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Abvc Biopharma, Inc. quarterly Debt-to-equity history and growth rate from Q4 2016 to Q3 2024.
  • Abvc Biopharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 81.1 %, a 66.4% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 81.1 -160 -66.4% Sep 30, 2024
Q2 2024 82.4 -207 -71.5% Jun 30, 2024
Q1 2024 123 -0.83 -0.67% Mar 31, 2024
Q4 2023 173 +94.2 +119% Dec 31, 2023
Q3 2023 241 +181 +302% Sep 30, 2023
Q2 2023 289 +234 +423% Jun 30, 2023
Q1 2023 124 +37.1 +43% Mar 31, 2023
Q4 2022 79.3 -45.8 -36.6% Dec 31, 2022
Q3 2022 60 -133 -68.9% Sep 30, 2022
Q2 2022 55.3 -435 -88.7% Jun 30, 2022
Q1 2022 86.4 -671 -88.6% Mar 31, 2022
Q4 2021 125 -4.56K -97.3% Dec 31, 2021
Q3 2021 193 +1.24K Sep 30, 2021
Q2 2021 490 +2.23K Jun 30, 2021
Q1 2021 758 +1.57K Mar 31, 2021
Q4 2020 4.68K +5.11K Dec 31, 2020
Q3 2020 -1.05K -759 -259% Sep 30, 2020
Q2 2020 -1.74K -1.51K -654% Jun 30, 2020
Q1 2020 -808 -596 -281% Mar 31, 2020
Q4 2019 -432 -222 -106% Dec 31, 2019
Q3 2019 -293 -68.2 -30.3% Sep 30, 2019
Q2 2019 -230 +14.6 +5.95% Jun 30, 2019
Q1 2019 -212 +17.6 +7.66% Mar 31, 2019
Q4 2018 -209 -1.67 -0.8% Dec 31, 2018
Q3 2018 -225 -95.5 -73.9% Sep 30, 2018
Q2 2018 -245 -143 -140% Jun 30, 2018
Q1 2018 -230 -128 -126% Mar 31, 2018
Q4 2017 -208 -74.1 -55.5% Dec 31, 2017
Q3 2017 -129 Sep 30, 2017
Q2 2017 -102 Jun 30, 2017
Q1 2017 -102 Mar 31, 2017
Q4 2016 -134 Dec 31, 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.